This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?

Eli Lilly (NYSE: LLY) manufactures a drug called tirzepatide, a GLP-1 dual receptor agonist, which it sells as Mounjaro for treating type 2 diabetes and Zepbound for weight loss. Tirzepatide became the world's best-selling drug in the third quarter. With year-to-date sales of $24.8 billion, it surpassed Keytruda, a blockbuster cancer immunotherapy drug made by pharmaceutical giant Merck.Considering the stunning achievement, is this a good time to invest $1,000 into Eli Lilly? Let's take a closer look.Third-quarter sales of Mounjaro and Zepbound combined were $10.1 billion, more than double the $4.4 billion they brought in during the third quarter of 2024. (Keytruda sales were $8.1 billion in the third quarter.) Sales of Mounjaro rose 109% in the quarter, while Zepbound sales rocketed 184% higher.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool